MIBG molecular imaging for evaluating response to chemotherapy in patients with malignant pheochromocytoma: Preliminary results

Cancer Imaging

Volumn 13, Issue 2, 2013, Pages 155-161

  Maurea, Simone ^a   Fiumara, Giovanni ^b   Pellegrino, Teresa ^c   Zampella, Emilia ^a   Assante, Roberta ^a   Mainenti, Pierpaolo ^a   Cuocolo, Alberto ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS SDN   (Italy)

^c CNR   (Italy)

Author keywords

Molecular imaging; Neuroendocrine tumor; Treatment monitoring

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CATECHOLAMINE; CYCLOPHOSPHAMIDE; DACARBAZINE; METADRENALIN; VANILMANDELIC ACID; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CATECHOLAMINE URINE LEVEL; CLINICAL ARTICLE; DENSITY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MALIGNANT PHEOCHROMOCYTOMA; MOLECULAR IMAGING; PHEOCHROMOCYTOMA; TISSUE COUNT DENSITY; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; VANILMANDELIC ACID;

EID: 84877860392     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2013.0017     Document Type: Article

References (19)

1. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007; 14: 569-585. doi:10.1677/ ERC-07-0074. PMid:17914089. (Pubitemid 350074048)
2. Andersen KF, Altaf R, Krarup-Hansen A, et al. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach. Cancer Treat Rev 2011; 37: 111-119. doi:10.1016/j.ctrv.2010.07.002. PMid:20675056.
3. Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109: 267-273. PMid:3395037.
4. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007; 92: 1217-1225. doi:10.1210/ jc.2006-1544. PMid:17284633. (Pubitemid 46556388)
5. Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008; 113: 2020-2028. doi:10.1002/cncr.23812. PMid:18780317.
6. Jacques S, Tobes MC, Sisson JC. Sodium dependency of uptake of nor-epinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res 1987; 47: 3920-3928. (Pubitemid 17108446)
7. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 2007; 14: 587-599. doi:10.1677/ERC- 07-0045. PMid:17914090. (Pubitemid 350074049)
8. Nguyen HH, Proye CA, Carnaille B, Combemale F, Pattou FN, Huglo D. Tumor size: the only predictive factor for 131-I MIBG uptake in phaeochromocytoma and paraganglioma. Aust NZ J Surg 1999; 69: 350-353. doi:10.1046/j.1440-1622.1999. 01570.x. (Pubitemid 29226193)
9. Maurea S, Cuocolo A, Imbriaco M, et al. Imaging characterization of benign and malignant pheochromocytoma or paraganglioma: comparison between MIBG uptake and MR signal intensity ratio. Ann Nucl Med 2012; 26: 670-675. doi:10.1007/ s12149-012-0624-1. PMid:22752959.
10. Maurea S, Lastoria S, Carac-o C, et al. Iodine-131-MIBG imaging to monitor chemotherapy response in advanced neuroblastoma: comparison with laboratory analysis. J Nucl Med 1994; 35: 1429-1435. PMid:8071687. (Pubitemid 24280447)
11. Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009; 94: 4757-4767. doi:10.1210/jc.2009- 1248. PMid:- 19864450.
12. Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endoc Relat Cancer 2004; 11: 423-436. doi:10.1677/ erc.1.00829. (Pubitemid 39331275)
13. Adler JT, Meyer-Rochow GY, Chen H, et al. Pheochromocytoma: current approaches and future directions. Oncologist 2008; 13: 779-793. doi:10.1634/theoncologist.2008-0043. PMid:18617683.
14. Kim EE, Haynie TP. Role of nuclear medicine in chemotherapy of malignant lesions. Semin Nucl Med 1985; 15: 12-20. PMid:3885397.
15. Cook GJR, Fogelman I. The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med 2001; 31: 206-211. PMid:11430527. (Pubitemid 32565551)
16. Ramanna L, Waxman A, Binney G, Waxman S, Mirra J, Rosen G. Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response. J Nucl Med 1990; 31: 567-572. PMid:2341892. (Pubitemid 20179694)
17. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: Does it make a difference? J Nucl Med 2007; 48: 36S-44S. PMid:17204719. (Pubitemid 47604941)
18. Nakazawa A, Higuchi T, Oriuchi N, Arisaka Y, Endo K. Clinical significance of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma. Eur J Nucl Med Mol Imaging 2011; 38: 1869-1875. doi:10.1007/s00259-011-1872-3. PMid:21732103.
19. Intenzo CM, Jabbour S, Lin HC, et al. Scintigraphic imaging of body neuroendocrine tumors. Radiographics 2007; 27: 1355-1369. doi:10.1148/rg. 275065729. PMid:17848696.